Treatment-naïve EGFR-mutant NSCLC patients with asymptomatic brain metastases received aumolertinib 165mg orally once daily….The overall ORR was 90.9% (20/22; 95% CI: 70.8-98.9). The CNS ORR was 86.3 (19/22; 95% CI: 65.1-97.1). The overall and CNS DCR were both 100%.

Au also achieved longer CNS median PFS over G in cFAS (29.0 vs 8.3 months; HR = 0.323; 95% CI, 0.181-0.576; P< 0.0001)….Au demonstrated superior clinical efficacy against CNS metastases over G as first-line therapy in EGFR-mutated advanced NSCLC, and the safety profile was consistent with that reported previously.

...The tumor harbors 1 of the 2 common epidermal growth factor receptor (EGFR) mutations known to be associated with Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EGFR) mutations, which may include T790M....

...A tumor tissue sample or blood sample was confirmed as an EGFR-sensitive mutation (21 L858R) by an investigator-approved local laboratory test. ...

...- The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), in combination with non-EGFR driver genes mutations assessed by central testing using tumour tissue sample....

...Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R) by ARMS; 6....

...Patients must has sensitizing EGFR mutation (e.g....

...The tumor harbors uncommon EGFR mutations (one of the following...

...Confirmed pathology of EGFR mutation positive（exon 19 deletion, L858R, T790M）NSCLC with brain metastases on enhanced MRI....

...Positive EGFR driver mutation (rare mutation other than 19 exon deletion or L858R) detected by tumor tissue or blood samples....

...Cohort A: Patients with EGFR exon 20 insertion, failure of first-line standard chemotherapy, or intolerance to chemotherapy Cohort B: Patients with uncommen EGFR mutations but without exon 19 deletion, L858R, T790M, and exon 20 insertion 3....

......

...Patients with primary non-small cell lung cancer with 2 common EGFR mutations（EGFR 19 Del or 21 L858R）; 6. ...

...Tumor tissue samples or blood samples of stage III NSCLC diagnosed as unresectable are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations). ...

...The patient had a classical mutation of EGFR (EGFR 19 Del or 21 L858R) in primary non-small cell lung cancer; 6. ...

...Patients with EGFR mutation positive stage IIB to IIIA NSCLC confirmed by histopathology and / or cytology; 3. ...

...Tumor tissue samples or blood samples diagnosed with stage IB-IIIA NSCLC are confirmed to be rare mutations in EGFR by laboratory tests [including rare mutations such as G719X, L861Q, S768I, and other EGFR site mutations alone or coexisting (except Ex19Del, L858R, T790M) and Ex20Ins) are available]. ...

...Patients with locally advanced (stage IIIB) or metastatic (stage IV) NON-small cell lung cancer with positive EGFR-resistant mutations who are unable to undergo curative surgery or radiotherapy and whose T790M mutation is confirmed; 2. ...

......

...- The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), in combination with tumor suppressor genes mutations assessed by central testing using tumour tissue sample....

...Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M....

...The tumor harbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations assessed by central testing using tumor tissue sample or blood sample....

...EGFR-sensitive mutations (include 19del or L858R mutation or coexist with other types of EGFR mutation)....

...In vitro experiments (1) Aged 18 to 75 years; (2) NSCLC diagnosed by histopathology and expressing any rare EGFR mutation such as 20 insertion, G719X, L861Q, S768I or L747S; (3) Malignant pleural effusion exists, and pleural effusion treatment is required; (4) The subjects themselves participated voluntarily and signed the informed consent in writing. ...

......

......

...Known EGFR-sensitive mutations (including exon 19 deletion or 21 L858R, both alone or co-existing or accompanied by other EGFR site mutations, with primary T790M mutation can be included, with exon 20 insertion mutation can not be included, blood/cytology/histology approved);...

...- Confirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) OR must have experienced clinical benefit from EGFR TKI, according to the Jackman criteria (followed by systemic objective progression (RECIST or World Health Organization [WHO]) while on continuous treatment with an EGFR TKI....

...The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing using tumour tissue sample or blood sample....

...- Tumor tissue samples or blood samples are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations)....

...The tumor harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19Del, L858R), either alone or in combination with other EGFR mutations including T790M, assessed by cobas® EGFR Mutation Test (Roche Diagnostics) or Xiamen AmoyDx EGFR (ADx-ARMS, Super-ARMS method) kit in site or central laboratory....

...Confirmation by the central laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M....

...Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M....

...Tumor tissue samples or blood samples are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations)....

...- Lung adenocarcinoma patient with EGFR sensitive mutation as confirmed by needle biopsy;...

...Tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity-ex19del or L858R-either alone or in combination with other EGFR mutations (eg, G719X, exon 20 insertions, S7681, L861Q) 4....

...NSCLC patients with EGFR mutation (19 deletion/21 L858R point mutation) or primary T790M mutation in pre-enrollment genetic testing....

...- Tumor tissue samples or blood samples were tested and confirmed as EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexisting with other EGFR site mutations)....

...epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation (alone or in combination with other EGFR mutations); 6....

...EGFR Exon 19del or Exon 21 L858R mutations; 4....

The 1-year DFS rate is 100%....This study demonstrated the significant efficacy of aumolertinib as adjuvant therapy for completely resected stage I-III EGFR-mutated NSCLC, and reported the consistent efficacy of aumolertinib in pts with co-mutation for the first time.

For advanced NSCLC patients with EGFR mutations, second-line treatment with almonertinib plus chemotherapy significantly improved PFS compared with almonertinib alone without a significant increase in adverse events, providing efficacy and safety.

We retrospectively collected data from NSCLC patients with EGFR-mutation who were intolerant after osimertinib treatment and received aumolertinib 110mg daily...15 patients subsequently received aumolertinib treatment. The 3-month conversion success rate was 100%, and overall ORR was 80% (2 CR, 10 PR, 95% CI: 51.9-95.7), DCR was 100%. ORR in subgroups with safety intolerance (rash and diarrhea) after treatment with osimertinib were respectively 87.5% (2 CR, 5 PR, 95% CI: 47.3-99.7) and 100% (2 CR, 4 PR).... This study confirmed safety and efficacy of aumolertinib in EGFR-mutation advanced NSCLC patients with safety intolerance after treatment with osimertinib...

Aumolertinib is a safety and efficacy choice in locally advanced or metastatic EGFR-mutant NSCLC pts who were intolerant to osimertinib treatment.

In patients with advanced NSCLC harboring uncommon EGFR mutations, high-dose aumolertinib demonstrated a tolerable safety profile and encouraging antitumor activity in NSCLC pts harboring uncommon EGFR mutations.

The study retrospectively analyzed 33 patients with advanced EGFR-mutated positive NSCLC with symptomatic brain metastases….The confirmed partial response (PR) were 9 (40.9%) patients and stable disease (SD) were 13 (59.1%) patients, all the patients had progressed. The ORR was 40.9% (9/22) and the DCR was 100 % (22/22). The median PFS and OS were 12.1months and 32.0 months, respectively. The main treatment regimens are aumolertinib monotherapy (40.9%), aumolertinib combined with WBRT (36.4%)....This retrospective study first demonstrated aumolertinib monotherapy or combined with local therapy had prolong the survival time and also improve the BM-related neurological symptoms and quality of life, no matter the first-line or therapy.

Intracranial oligometastatic patients with EGFR sensitive mutations (EGFR-TKIs naive) were enrolled and received aumolertinib 110 mg daily until intracranial disease progression….After administration of aumolertinib, the best response of all patients in intracranial and extracranial lesions was partial response (PR), with an iORR of 100%.

This study enrolled pts with stage IIA-IVB EGFR+ NSCLC who received aumolertinib alone as first-line therapy...Overall, ORR and DCR were 74.2% and 97.0%, respectively...ORR was 71.4% and 77.4% for pts ≥65 and <65 yr, respectively, and DCR was 97.1% and 96.8%, respectively.

Aumolertinib showed preliminary efficacy and good tolerability in intracranial oligometastatic EGFR mutated NSCLC.

Aumolertinib showed preliminary antitumor activity with a manageable safety profile as first-line therapy in EGFR-mutant NSCLC patients with brain metastases.

100 patients’ medical records were reviewed for EGFR mutated ANSCLC treated with almonertinib, Data from 2020/4/1 to 2021/3/1 in Henan Cancer Hospital were also collected and retrospectively analyzed…. The ORR of the patients who received almonertinib as first-line treatment (n=45) was 71%, mPFS was 16.7 months, and mOS was still not reached....Almonertinib has been shown good efficacy and safety in EGFR-mutant ANSCLC.... Elevated creatine kinase is an important predictor of longer mPFS.

At the data cutoff, all patients have no symptoms of tumor recurrence, 25 (37.9%) patients have been followed up for over 1 year. At 12 months, 100% patients were alive and disease-free...This is the first study to demonstrate that aumolertinib has preliminary efficacy and a tolerable safety profile in patients with completely resected stage I-III NSCLC harboring EGFR mutations.

Further tissue and imaging analysis revealed EGFR-mutant stage IV (cT2N3M1) NSCLC...After 2 weeks of aumolertinib administration, the patient showed significant improvement...

Their inhibition effects on cell proliferation and metastasis were firstly compared upon three human NSCLC cell lines in vitro...Aumolertinib-pemetrexed combined therapy is promising for EGFR mutant NSCLC but only in right administration sequence.